Try our Advanced Search for more refined results

VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION

Track this case

Case overview

Case Number:

1:19-md-02875

Court:

New Jersey

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

Renee Marie Bumb

Firms

Companies

Sectors & Industries:

  1. December 04, 2025

    Vivimed To Pay $1.9M To End Losartan Economic Loss Claims

    Vivimed has agreed to pay $1.9 million to settle economic loss claims from a class of consumers and insurers related to its losartan product in sprawling multidistrict litigation over contaminated blood pressure medication, according to a Wednesday filing.

  2. November 12, 2025

    Valsartan Cancer Expert Blocked, Ending First Injury Trial

    What was set to be the first bellwether case in the sprawling multidistrict litigation over contaminated blood pressure medication Valsartan was decided Monday when a New Jersey federal judge excluded as "pure speculation" the plaintiff's medical expert who testified that the drug caused a patient's liver cancer.

  3. April 08, 2025

    Expert And 'Worthlessness Theory' Ejected In Valsartan MDL

    Patients and insurers who claim they were ripped off when purchasing the contaminated blood pressure medication Valsartan won't be able to argue that the drug was worthless as a matter of law, a New Jersey federal judge overseeing the multidistrict litigation has ruled, casting doubt that the plaintiffs will secure a full refund for their purchase.

  4. August 05, 2024

    Chinese Drug Co. Says Sanctions In Valsartan MDL Too Harsh

    Chinese drug firm Zhejiang Huahai Pharmaceutical Co. Ltd. told a New Jersey federal court Friday that sanctions authorizing two adverse jury instructions in multidistrict litigation over generic drugs contaminated with carcinogens should be overturned, arguing the plaintiffs did not allege the bad faith required for such a harsh penalty.

  5. May 14, 2024

    Chinese Drug Co. Sanctioned After 'Tortuous' 3-Year Info Fight

    Chinese drug firm Zhejiang Huahai Pharmaceutical Co. Ltd. has been hit with sanctions after its chief executive officer failed to sit for a court-ordered deposition in sprawling multidistrict litigation taking place in New Jersey over generic drugs that U.S. authorities say were contaminated with carcinogens.

  6. February 08, 2023

    Consumers And Insurers Get Class Cert. In Valsartan MDL

    A New Jersey federal judge on Wednesday certified classes of consumers and insurers who claim they lost money by purchasing the contaminated blood pressure drug Valsartan, as well as two classes of consumers seeking medical monitoring for cancer potentially caused by the drug.

  7. April 05, 2022

    Valsartan MDL Judge OKs Out-Of-State Litigants, More Claims

    A New Jersey federal judge ruled Tuesday that multidistrict litigation against drug manufacturers, pharmacies and wholesalers over carcinogens in blood pressure drugs can expand to include out-of-state litigants and warranty claims under laws in nearly two dozen jurisdictions.

  8. December 22, 2021

    Judge Overrules 'State Secrets' Concerns In Valsartan MDL

    A New Jersey federal judge backed a special master's order that Zhejiang Huahai Pharmaceutical Co. Ltd. must produce documents it sought to shield in multidistrict litigation over blood pressure drugs such as valsartan, warning that parties can't exploit uncertainties in foreign state secrets laws to thwart U.S. lawsuits.

  9. June 22, 2021

    Chinese Drug Co. Chief Must Testify In Tainted Valsartan MDL

    The special master in multidistrict litigation alleging that pharmaceutical companies sold generic drugs containing the active ingredient valsartan that were tainted with carcinogens ruled on Tuesday that the president of Zhejiang Huahai Pharmaceutical Co. Ltd. can't be blocked from giving a deposition in the case.

  10. January 29, 2021

    Drugmakers Must Face Fraud Claims In Valsartan MDL

    A New Jersey federal judge said Friday he won't toss fraud claims against drug manufacturers, but will toss the claims against wholesalers and pharmacies, in multidistrict litigation alleging they took part in distributing generic drugs containing the active ingredient valsartan that were tainted with carcinogens.